The long acting GnRH antagonist degarelix will be tested for the treatment of women with endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.
Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing recurrence after surgery at least in 20-50% after 5 years of follow-up. The long acting GnRH antagonist degarelix, which do not have the flare-up effect at the opposite of GnRH agonist and strongly suppress LH secretion and thecal cell activity may show a better effects on endometrial implants than GnRH agonist.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
360
180 women will be treated with degarlix 120 mg, in only one administration covering three months
180 women will be treated with leuprolide acetate11.25 only once covering three months
Albania Spitali Amerikan
Tirana, Albania
Nadezda Women's Health Hospital
Sofia, Bulgaria
Cerm-Hungaria
Rome, Italy
disease free time
time without pain symptoms due to the disease recurrence
Time frame: 24 months
time of disappearance pain
time needed during treatment to improve the pain symptoms
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.